AndreaBozzo/ceres-open-data-index huggingface dataset:
Monthly Prescription Drug Plan Formulary and Pharmacy Network Information

The Monthly Prescription Drug Plan Formulary and Pharmacy Network Information files contain formulary and pharmacy network data for Medicare Prescription Drug Plans and Medicare Advantage (MA) Prescription Drug Plans (with the exception of employer and Program of All-Inclusive Care for the Elderly plans).

 

These non-identifiable files are available on a monthly basis and are comprised of the following tables:


	Plan Information - Information such as plan name, contract ID, plan ID, service area, and plan type.
	Geographic Locator - MA and Prescription Drug Plans region codes and county codes.
	Basic Drugs Formulary - Formulary details for each plan including National Drug Codes (NDCs), cost share tier level, and indicators for step therapy, quantity limits, prior authorization, and a newly added Selected Drug flag.
	Excluded Drugs Formulary - Enhanced alternative plans may elect to provide a supplemental benefit and cover excluded drugs. File includes formulary details for excluded drugs that are covered by the plan (for enhanced alternative plans only).
	Beneficiary Cost - Plan level cost sharing details for preferred, non-preferred, and mail order network pharmacies.
	Pharmacy Network - National Provider Identifier (NPI) numbers for each network pharmacy including preferred, retail, and mail order indicators, and brand, generic, and selected drug dispensing fees for 30/60/90 days supply, respectively.
	Indication Based Coverage Formulary File - Includes drugs covered based on FDA-approved indication for each plan.
	Insulin Beneficiary Cost File - Plan level copay and coinsurance amounts for insulin at preferred, non-preferred and mail order network pharmacies.


 

These are large files and can take time to download. 
 

Please read the “Agreement for Use” in the Resources section below. This document contains important information regarding timeframes for obtaining data as well as data accuracy and integrity.

 

The Quarterly Prescription Drug Plan Formulary, Pharmacy Network, and Pricing Information is also available to access for the quarterly level information. 

 

Please note: The Part D benefit year information for plans become available in October of the year prior. For example, year 2026 data is available in the October, November and December 2025 monthly files. Year 2026 data continues to be available in the January through September 2026 monthly files, then beginning in October of 2026 year 2027 data becomes available.

Estimated release dates for upcoming 2026 monthly data (files reflect data for the month in which the file is released):


	7/29/26
	8/26/26
	9/23/26


Files older than contract year 2019 can be purchased.
Public Health Statistics - Preterm births in Chicago, by year, 1999 – 2009 - Historical

Note: This dataset is historical only and there are not corresponding datasets for more recent time periods. For that more-recent information, please visit the Chicago Health Atlas at https://chicagohealthatlas.org.

This dataset contains the annual number of preterm births and the percent of total births these preterm births represent, with corresponding 95% confidence intervals, by Chicago community area, for the years 1999 – 2009.  See the full dataset description for more information: http://bit.ly/M7AyBL
2011-2012 NSDUH State Estimates of Substance Use and Mental Disorders

State estimates for 25 measures of substance use and mental disorders based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs) are provided. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older. State and regional estimates are based on a small area estimation (SAE) methodology in which State-level NSDUH data are combined with county and census block group/tract-level data from the State.
Compound 526851: 2,3-Dimethyl-4-isopropenyl-1-cyclopentanone

Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethyl-4-prop-1-en-2-ylcyclopentan-1-one. Molecular Formula: C10H16O. Molecular Weight: 152.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Saxagliptin and metformin hydrochloride

Saxagliptin and Metformin Hydrochloride is a prescription extended-release oral tablet combining metformin (a biguanide) and saxagliptin (a DPP-4 inhibitor) to help manage type 2 diabetes by lowering blood sugar levels. Available in strengths like 500mg metformin with 5mg saxagliptin, manufactured by Dr. Reddy's Laboratories Inc. This information was generated using AI and is provided for informational and research purposes only.
Compound 526407: 1,1,1-Trifluorodecane

Chemical compound data from PubChem database. IUPAC Name: 1,1,1-trifluorodecane. Molecular Formula: C10H19F3. Molecular Weight: 196.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525210: 5-Chloroheptanoic acid, chloromethyl ester

Chemical compound data from PubChem database. IUPAC Name: chloromethyl 5-chloroheptanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
New Hampshire: 2011-2012 NSDUH

This report presents New Hampshire\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.
Weight-modification trials in older adults: what should the outcome measure be?

Background
          Overweight older adults are often counseled to lose weight, even though there is little evidence of excess mortality in that age group. Overweight and underweight may be more associated with health status than with mortality, but few clinical trials of any kind have been based on maximizing years of healthy life (YHL), as opposed to years of life (YOL).
        
        
          Objective
          This paper examines the relationship of body mass index (BMI) to both YHL and YOL. Results were used to determine whether clinical trials of weight-modification based on improving YHL would be more powerful than studies based on survival.
        
        
          Design
          We used data from a cohort of 4,878 non-smoking men and women aged 65–100 at baseline (mean age 73) and followed 7 years. We estimated mean YHL and YOL in four categories of BMI: underweight, normal, overweight, and obese.
        
        
          Results
          Subjects averaged 6.3 YOL and 4.6 YHL of a possible 7 years. Both measures were higher for women and whites. For men, none of the BMI groups was significantly different from the normal group on either YOL or YHL. For women, the obese had significantly lower YHL (but not YOL) than the normals, and the underweight had significantly lower YOL and YHL. The overweight group was not significantly different from the normal group on either measure.
        
        
          Conclusions
          Clinical trials of weight loss interventions for obese older women would require fewer participants if YHL rather than YOL was the outcome measure. Interventions for obese men or for the merely overweight are not likely to achieve differences in either YOL or YHL. Evaluations of interventions for the underweight (which would presumably address the causes of their low weight) may be conducted efficiently using either outcome measure.
Florida 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment

The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.
Compound 525160: Heptaethylene glycol, diacetate

Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-[2-(2-acetyloxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl acetate. Molecular Formula: C18H34O10. Molecular Weight: 410.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Drug Abuse Warning Network US (DAWN-NS-1997)

<p>The Drug Abuse Warning Network (DAWN) survey is designed to<br />
capture data on emergency department (ED) episodes that are induced by<br />
or related to the use of an illicit, prescription, or over-the-counter<br />
drug. For purposes of this collection, a drug "episode" is an ED visit<br />
that was induced by or related to the use of an illegal drug or the<br />
nonmedical use of a legal drug for patients aged six years and<br />
older. A drug "mention" refers to a substance that was mentioned<br />
during a drug-related ED episode. Because up to four drugs can be<br />
reported for each drug abuse episode, there are more mentions than<br />
episodes in the data. Individual persons may also be included more<br />
than once in the data. Within each facility participating in DAWN, a<br />
designated reporter, usually a member of the emergency department or<br />
medical records staff, was responsible for identifying drug-related<br />
episodes and recording and submitting data on each case. An episode<br />
report was submitted for each patient visiting a DAWN emergency<br />
department whose presenting problem(s) was/were related to their own<br />
drug use. DAWN produces estimates of drug-related emergency department<br />
visits for 50 specific drugs, drug categories, or combinations of<br />
drugs, including the following: acetaminophen, alcohol in combination<br />
with other drugs, alprazolam, amitriptyline, amphetamines, aspirin,<br />
cocaine, codeine, diazepam, diphenhydramine, fluoxetine,<br />
heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam,<br />
marijuana/hashish, methadone, methamphetamine, and PCP/PCP in<br />
combination with other drugs. The use of alcohol alone is not<br />
reported. The route of administration and form of drug used (e.g.,<br />
powder, tablet, liquid) are included for each drug. Data collected for<br />
DAWN also include drug use motive and total drug mentions in the<br />
episode, as well as race, age, patient disposition, reason for ED<br />
visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.</p>
Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats

Background
          We are investigating a double transgenic rat (dTGR) model, in which rats transgenic for the human angiotensinogen and renin genes are crossed. These rats develop moderately severe hypertension but die of end-organ cardiac and renal damage by week 7. The heart shows necrosis and fibrosis, whereas the kidneys resemble the hemolytic-uremic syndrome vasculopathy. Surface adhesion molecules (ICAM-1 and VCAM-1) are expressed early on the endothelium, while the corresponding ligands are found on circulating leukocytes. Leukocyte infiltration in the vascular wall accompanies PAI-1, MCP-1, iNOS and Tissue Factor expression. Furthermore we show evidence that Ang II causes the upregulation of NF-kB in our model.
        
        
          Methods
          We started PDTC-treatment on four weeks old dTGR (200 mg/kg sc) and age-matched SD rats.. Blood-pressure- and albuminuria- measurements were monitored during the treatement period (four weeks). The seven weeks old animals were killed, hearts and kidneys were isolated and used for immunohistochemical-and electromobility shift assay analsis.
        
        
          Results
          Chronic treatment with the antioxidant PDTC decreased blood pressure (162 ± 8 vs. 190 ± 7 mm Hg, p = 0.02). Cardiac hypertrophy index was significantly reduced (4.90 ± 0.1 vs. 5.77 ± 0.1 mg/g, p < 0.001) compared to dTGR. PDTC reduced 24 h albuminuria by 85 % (2.7 ± 0.5 vs. 18.0 ± 3.4 mg/d, p < 0.001) and prevented death significantly. Vascular injury was ameliorated in small renal and cardiac vessels. PDTC inhibited NF-κB binding activity in heart and kidney. Immunohistochemical analysis shows increased expression of the p65 NF-κB subunit in the endothelium, smooth muscles cells of damaged small vessels, infiltrated cells, glomeruli, tubuli and collecting ducts of dTGR. PDTC markedly reduced the immunoreactivity of p65.
        
        
          Conclusion
          Our data show that inhibition of NF-κB by PDTC markedly reduces inflammation, iNOS expression in the dTGR most likely leading to decreased cytotoxicity, and cell proliferation. Thus, NF-κB activation plays an important role in ANG II-induced end-organ damage.
Compound 528645: m-Trimethylsilyloxyphenyl(trimethylsilyloxy)trimethylsilylacrylate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-trimethylsilyloxy-3-(3-trimethylsilyloxyphenyl)propanoate. Molecular Formula: C18H34O4Si3. Molecular Weight: 398.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530268: Pentadecane, 8-butyl-7-pentyl

Chemical compound data from PubChem database. IUPAC Name: 7,8-dipentylpentadecane. Molecular Formula: C25H52. Molecular Weight: 352.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Information Memorandum (IM-92-16)

This Information Memorandum (IM) establishes Fiscal Year (FY) 1992 Allotments for Title IV-B and Procedures for Applyinq for:

1)    Funds Representinq the Difference Between What a State Has Been Awarded and Its Full Share of Funds Available Under Title IV-B in FY 1992;
2)    Realloted IV-B Funds; and
3)    Funds to be Transferred from Title IV-E-Foster Care.

Metadata-only record linking to the original dataset. Open original dataset below.
The probability of cost-effectiveness

Background
          The study of cost-effectiveness comparisons between competing medical interventions has led to a variety of proposals for quantifying cost-effectiveness. The differences between the various approaches can be subtle, and one purpose of this article is to clarify some important distinctions.
        
        
          Discussion
          We discuss alternative measures in the framework of individual, patient-level, incremental net benefits. In particular we examine the probability of cost-effectiveness for an individual, proposed by Willan.
        
        
          Summary
          We argue that this is a useful addition to the range of cost-effectiveness measures, but will be of secondary interest to most decision makers. We also demonstrate that Willan's proposed estimate of this probability is logically flawed.
Compound 525789: 4-Methyl-2-pentyloxazole

Chemical compound data from PubChem database. IUPAC Name: 4-methyl-2-pentyl-1,3-oxazole. Molecular Formula: C9H15NO. Molecular Weight: 153.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530021: Hexadecane, 7-pentyl-8-propyl

Chemical compound data from PubChem database. IUPAC Name: 7-pentyl-8-propylhexadecane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
A glutamine-amidotransferase-like protein modulates FixT anti-kinase activity in

Background
          Nitrogen fixation gene expression in Sinorhizobium meliloti, the alfalfa symbiont, depends on a cascade of regulation that involves both positive and negative control. On top of the cascade, the two-component regulatory system FixLJ is activated under the microoxic conditions of the nodule. In addition, activity of the FixLJ system is inhibited by a specific anti-kinase protein, FixT. The physiological significance of this negative regulation by FixT was so far unknown.
        
        
          Results
          We have isolated by random Tn5 mutagenesis a S. meliloti mutant strain that escapes repression by FixT. Complementation test and DNA analysis revealed that inactivation of an asparagine synthetase-like gene was responsible for the phenotype of the mutant. This gene, that was named asnO, encodes a protein homologous to glutamine-dependent asparagine synthetases. The asnO gene did not appear to affect asparagine biosynthesis and may instead serve a regulatory function in S. meliloti. We provide evidence that asnO is active during symbiosis .
        
        
          Conclusions
          Isolation of the asnO mutant argues for the existence of a physiological regulation associated with fixT and makes it unlikely that fixT serves a mere homeostatic function in S. meliloti. Our data suggest that asnO might control activity of the FixT protein, in a way that remains to be elucidated. A proposed role for asnO might be to couple nitrogen fixation gene expression in S. meliloti to the nitrogen needs of the cells.
Olmesartan medoxomil and hydrochlorothiazide

Olmesartan Medoxomil and Hydrochlorothiazide is a prescription medication combining two drugs to treat high blood pressure. Olmesartan blocks a substance that tightens blood vessels, while hydrochlorothiazide is a diuretic that helps remove excess fluid. It's taken orally as tablets in doses like 20mg/12.5mg, 40mg/12.5mg, or 40mg/25mg. This information was generated using AI and is provided for informational and research purposes only.
4.17a Facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility: 2011. Number

This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.
Patent AT-E399676-T1: [Translated] METHOD FOR PRODUCING A SEATING SYSTEM

The present invention discloses a seating system that includes a seat back ( 20 ) with one or more plastic panels ( 22 ) that extend across a lateral distance of the seat back ( 20 ). The seat back ( 20 ) preferably includes one or more reinforcements ( 30 ) attached to the plastic panels ( 22 ).
Permutation-validated principal components analysis of microarray data

Background
          In microarray data analysis, the comparison of gene-expression profiles with respect to different conditions and the selection of biologically interesting genes are crucial tasks. Multivariate statistical methods have been applied to analyze these large datasets. Less work has been published concerning the assessment of the reliability of gene-selection procedures. Here we describe a method to assess reliability in multivariate microarray data analysis using permutation-validated principal components analysis (PCA). The approach is designed for microarray data with a group structure.
        
        
          Results
          We used PCA to detect the major sources of variance underlying the hybridization conditions followed by gene selection based on PCA-derived and permutation-based test statistics. We validated our method by applying it to well characterized yeast cell-cycle data and to two datasets from our laboratory. We could describe the major sources of variance, select informative genes and visualize the relationship of genes and arrays. We observed differences in the level of the explained variance and the interpretability of the selected genes.
        
        
          Conclusions
          Combining data visualization and permutation-based gene selection, permutation-validated PCA enables one to illustrate gene-expression variance between several conditions and to select genes by taking into account the relationship of between-group to within-group variance of genes. The method can be used to extract the leading sources of variance from microarray data, to visualize relationships between genes and hybridizations and to select informative genes in a statistically reliable manner. This selection accounts for the level of reproducibility of replicates or group structure as well as gene-specific scatter. Visualization of the data can support a straightforward biological interpretation.
Method for non-invasively recording electrocardiograms in conscious mice

Background
          The rapid increase in the development of mouse models is resulting in a growing demand for non-invasive physiological monitoring of large quantities of mice. Accordingly, we developed a new system for recording electrocardiograms (ECGs) in conscious mice without anesthesia or implants, and created Internet-accessible software for analyzing murine ECG signals. The system includes paw-sized conductive electrodes embedded in a platform configured to record ECGs when 3 single electrodes contact 3 paws.
        
        
          Results
          With this technique we demonstrated significantly reduced heart rate variability in neonates compared to adult mice. We also demonstrated that female mice exhibit significant ECG differences in comparison to age-matched males, both at baseline and in response to β-adrenergic stimulation.
        
        
          Conclusions
          The technology we developed enables non-invasive screening of large numbers of mice for ECG changes resulting from genetic, pharmacological, or pathophysiological alterations. Data we obtained non-invasively are not only consistent with what have been reported using invasive and expensive methods, but also demonstrate new findings regarding gender-dependent and age-dependent variations in ECGs in mice.